CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication

• click to rate

  Posted by Two Blokes Jun 24 - Filed in Stock - 3 views
  
  CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.